← Back to Awards
NIHNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Development of an Optimized Adjuvanted TB Vaccine
- Institution
- University of Montana, MT
- Principal investigator
- Jay Evans
- Funding
- $253K
- Duration
- 2021–2025
32/100
Abstract
Vaccine Adjuvant Discovery Program: To develop a lead, optimized adjuvanted tuberculosis (TB) vaccine for IM or IN administration using specified adjuvants in combination with recombinant or circRNA TB antigens within the context of a vaccine to prevent TB.
LOADING MOONBASE SCORE
Questions for University of Montana
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, scored first.
- NIH · University of Montana55
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM
Jay Evans · $1.6M · 2023–2026
- NIH · University of Montana48
Identification of Novel Syk/Raf-1 Mediated CLR Ligands as Vaccine Adjuvants
Jay Evans · $1.6M · 2025–2026
- NIH · University of Montana42
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM
Jay Evans · $5.5M · 2023–2028